Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer

Journal:

Nature Communications

Published:

2026-02-25

DOI:

10.1038/s41467-026-70001-5

Affiliations:

10

Authors:

11

Go to article

Institutions	Authors	Share
State Key Laboratory of Molecular Oncology, China	3.500000	0.32
Cancer Institute and Hospital, CAMS & PUMC, China	3.000000	0.27
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.500000	0.14
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.09
The Affiliated Hospital of Qingdao University, China	1.000000	0.09
Harvard Medical School (HMS), United States of America (USA)	0.500000	0.05
Henan Academy of Innovations in Medical Science, China	0.500000	0.05

Interested in Oncology and Carcinogenesis?